{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:50:39Z","timestamp":1787982639680,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82122016"],"award-info":[{"award-number":["No. 82122016"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2017YFA0105804"],"award-info":[{"award-number":["2017YFA0105804"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40123-024-00884-4","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T14:01:44Z","timestamp":1710770504000},"page":"1239-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Tianyu","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuening","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-6362","authenticated-orcid":false,"given":"Wenru","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"3","key":"884_CR1","first-page":"192","volume":"7","author":"NS Chan","year":"2018","unstructured":"Chan NS, Choi J, Cheung CMG. Pediatric uveitis. Asia Pac J Ophthalmol (Phila). 2018;7(3):192\u20139.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"4","key":"884_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.rdc.2021.07.005","volume":"47","author":"MH Chang","year":"2021","unstructured":"Chang MH, et al. Uveitis in children and adolescents. Rheum Dis Clin North Am. 2021;47(4):619\u201341.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"884_CR3","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1111\/aos.15012","volume":"100","author":"CV Kouwenberg","year":"2022","unstructured":"Kouwenberg CV, Koopman-KalininaAyuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol. 2022;100(4):e994\u20131001.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"884_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00417-018-3928-6","volume":"256","author":"I Deitch","year":"2018","unstructured":"Deitch I, et al. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):801\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"884_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40674-017-0057-z","volume":"3","author":"AB Sood","year":"2017","unstructured":"Sood AB, Angeles-Han ST. An update on treatment of pediatric chronic non-infectious uveitis. Curr Treatm Opt Rheumatol. 2017;3(1):1\u201316.","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"2","key":"884_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jfo.2020.08.003","volume":"44","author":"N Stolowy","year":"2021","unstructured":"Stolowy N, et al. Immunosuppressive therapy in severe or chronic pediatric uveitis: review of the literature. J Fr Ophtalmol. 2021;44(2):252\u20138.","journal-title":"J Fr Ophtalmol"},{"key":"884_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.813696","volume":"9","author":"H Song","year":"2022","unstructured":"Song H, et al. The efficacy and safety of adalimumab in treating pediatric noninfectious chronic anterior uveitis with peripheral retinal vascular leakage: a pilot study. Front Med (Lausanne). 2022;9: 813696.","journal-title":"Front Med (Lausanne)"},{"key":"884_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1546-0096-11-16","volume":"11","author":"G Simonini","year":"2013","unstructured":"Simonini G, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-\u03b1 therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"17","key":"884_CR9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"884_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/keaa595","volume":"60","author":"I Maccora","year":"2021","unstructured":"Maccora I, et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology (Oxford). 2021;60(2):568\u201387.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"884_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semarthrit.2014.03.001","volume":"44","author":"G Simonini","year":"2014","unstructured":"Simonini G, et al. Does switching anti-TNF\u03b1 biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014;44(1):39\u201346.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"884_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","volume":"13","author":"KC LaMattina","year":"2017","unstructured":"LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181\u20138.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"884_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10792-011-9430-3","volume":"31","author":"P Neri","year":"2011","unstructured":"Neri P, et al. Adalimumab (HUMIRA\u2122): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol. 2011;31(2):165\u201373.","journal-title":"Int Ophthalmol"},{"issue":"4","key":"884_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4103\/0974-9233.71588","volume":"17","author":"P Neri","year":"2010","unstructured":"Neri P, et al. Adalimumab (HUMIRA\u2122) in ophthalmology: a review of the literature. Middle East Afr J Ophthalmol. 2010;17(4):290\u20136.","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"3","key":"884_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","volume":"28","author":"E Silvestri","year":"2020","unstructured":"Silvestri E, et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et\u2019s syndrome. Inflammopharmacology. 2020;28(3):711\u20138.","journal-title":"Inflammopharmacology"},{"issue":"3","key":"884_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"884_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, et al. Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the Freiburg Visual Acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236\u201340.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"884_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10792-008-9263-x","volume":"30","author":"I Tugal-Tutkun","year":"2010","unstructured":"Tugal-Tutkun I, Herbort CP, Khairallah M. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539\u201352.","journal-title":"Int Ophthalmol"},{"key":"884_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","volume":"207","author":"S Horton","year":"2019","unstructured":"Horton S, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol Participants of the SYCAMORE trial. Am J Ophthalmol. 2019;207:170\u20134.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"884_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003\u201311.","journal-title":"Ann Rheum Dis"},{"key":"884_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2139274","author":"HK Sonmez","year":"2022","unstructured":"Sonmez HK, Evereklioglu C, GulmezSevim D. Prompt and sustained suppression of intraocular inflammation with adalimumab in pediatric patients with non-infectious uveitis resistant to traditional managements: a 6-month follow-up research. Ocul Immunol Inflamm. 2022. https:\/\/doi.org\/10.1080\/09273948.2022.2139274.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"884_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.20404","volume":"63","author":"G Simonini","year":"2011","unstructured":"Simonini G, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"884_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, et al. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104(3):246\u201350.","journal-title":"Arch Dis Child"},{"issue":"6","key":"884_CR24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/art.40885","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, et al. 2019 American College of Rheumatology\/Arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019;71(6):864\u201377.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"884_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ajo.2015.04.016","volume":"160","author":"MA Lerman","year":"2015","unstructured":"Lerman MA, et al. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol. 2015;160(1):193-200.e1.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"884_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaapos.2015.12.006","volume":"20","author":"C Castiblanco","year":"2016","unstructured":"Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J aapos. 2016;20(2):145\u20137.","journal-title":"J aapos"},{"issue":"6","key":"884_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3899\/jrheum.161336","volume":"44","author":"G Simonini","year":"2017","unstructured":"Simonini G, et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis. J Rheumatol. 2017;44(6):822\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"884_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s13063-020-04796-z","volume":"21","author":"NR Acharya","year":"2020","unstructured":"Acharya NR, et al. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Trials. 2020;21(1):887.","journal-title":"Trials"},{"issue":"3","key":"884_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"D Wendling","year":"2011","unstructured":"Wendling D, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503\u201310.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"884_CR30","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s40123-023-00712-1","volume":"12","author":"A Vitale","year":"2023","unstructured":"Vitale A, et al. Efficacy and safety of adalimumab in pediatric non-infectious non-anterior uveitis: real-life experience from the international AIDA network uveitis registry. Ophthalmol Ther. 2023;12(4):1957\u201371.","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"884_CR31","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/jid.2013.78","volume":"133","author":"A Nast","year":"2013","unstructured":"Nast A, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol. 2013;133(8):1963\u201370.","journal-title":"J Invest Dermatol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00884-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-00884-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00884-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:54:13Z","timestamp":1713898453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-00884-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-00884-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tianyu Tao, Shizhao Yang, Daquan He, Xuening Peng, Zhenyu Wang, Qi Jiang, Tianfu Wang, and Wenru Su have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The studies involving human participants were reviewed and approved by Zhongshan Ophthalmic Center Ethics Committee (No. 2019058). The patients and their legal guardian provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s), and minor(s)\u2019 legal guardian\/next of kin, for the publication of any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}